Abstract: The invention relates to cyclic bioisosteres of derivatives of a purine system having a general structural formula where R=Li, Na, K, R1=—H, —NH2, —Br, —Cl, —OH, —COOH, B=—N?, —CH?, Z=—CH?, —N?, A=—N? at B=—N?, Z=—CH—, A=—CH? at B=—N?, Z=—CH—, A=—CH? at B=—N?, Z=—N?, A=—CH? at B=—CH?, Z=—CH?, A=—CH? at B=—CH?, Z=—N?, and their pharmacologically acceptable salts having a normalizing effect on endocellular processes, in particular, it is capable eliminating endocellular metabolic acidosis and capable of binding excessively formed free radicals, in particular, free-radical forms of oxygen, capable of normalizing the nitrergic mechanisms of the cells, and also capable of interreacting with adenosine-sensitive receptors on the membrane of non-nuclear cells and in nuclei-containing cells to decrease the aggregation of thrombocytes. The compounds according to the invention have hepatoprotective effect and can be used for producing pharmaceutical compositions on their base.

Abstract: The present invention relates to a treatment of high-level waste of radiochemical production containing radionuclides and macro-admixtures including sodium. The method of extraction of radionuclides by processing acidic aqueous waste solutions by extractants containing macrocyclic compounds selected from the group of crown ethers having aromatic fragments containing alkyl and/or hydroxyalkyl substituents of a linear and/or branched structure, and/or cyclohexane fragments containing alkyl and/or hydroxyalkyl substituents of a linear and/or branched structure, and/or fragments of —O—CHR—CH2O—, where R is the normal or branched alkyl or hydroxyalkyl in organic solvents containing polyfluorinated telomeric alcohol 1,1,7-trihydrododecafluoroheptanol-1 having the formula H(CF2CF2)nCH2OH, where n=3, and a mixture of polyoxyethylene glycol ethers of synthetic primary higher aliphatic alcohols of a fraction C12-C14 of a general formula CnH2n+1O(C2H4O)mH, where n=12-14, m=2 is proposed.

Abstract: The invention relates to application of compounds having a general structural formula: where R= ?Li, Na, K, R1=—H, —NH2, —Br, —Cl, —OH, —COOH, B=—N?, —CH?, Z=—CH?, —N?, A=—N? at B=—N?, Z=—CH—, A=—CH? at B=—N?, Z=—CH—, A=—CH? at B=—N?, Z=—N?, A=—CH? at B=—CH?, Z=—CH?, A=—CH? at B=—CH?, Z=—N?, and/or their pharmacologically acceptable salts as an active ingredient having appropriate activity with respect to nitrergic and/or dopaminergic systems, in a pharmaceutical composition as neuroprotector for improvement of the cognitive function and for normalization of psychophysiological status, as well as for treatment of a wide spectrum of psychological diseases, cardiovascular diseases, diseases caused by substance abuse, and diseases caused by a hyperactive immune system in mammals including human beings.

Abstract: The invention relates to cyclic bioisosteres of derivatives of a purine system having a general structural formula where R?Li, Na, K, R1?—H, —NH2, —Br, —Cl, —OH, —COOH, B?—N?, —CH?, Z=-CH?, —N?, A=-N? at B?—N?, Z=-CH—, A=-CH? at B?—N?, Z=-CH—, A=-CH? at B?—N?, Z=-N?, A=-CH? at B?—CH?, Z=-CH?, A=-CH? at B?—CH?, Z=-N?, and their pharmacologically acceptable salts having a normalizing effect on endocellular processes, in particular, it is capable eliminating endocellular metabolic acidosis and capable of binding excessively formed free radicals, in particular, free-radical forms of oxygen, capable of normalizing the nitrergic mechanisms of the cells, and also capable of interreacting with adenosine-sensitive receptors on the membrane of non-nuclear cells and in nuclei-containing cells to decrease the aggregation of thrombocytes. The compounds according to the invention have hepatoprotective effect and can be used for producing pharmaceutical compositions on their base.